8:01 AM ET
8-K
Licensing Deal
Keros Therapeutics Licensing Deal with Takeda Pharmaceuticals U.S.A., Inc. Worth $20M
Keros Therapeutics announced it will receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The payment is part of a global license agreement that includes potential milestones exceeding $1.1 billion. Keros intends to distribute 25% of the net cash proceeds from this milestone to its stockholders.
- Value
- $20M
- Counterparty
- Takeda Pharmaceuticals U.S.A., Inc.